Omnicell (OMCL) Tops Q3 EPS by 17c

Go back to Omnicell (OMCL) Tops Q3 EPS by 17c

Omnicell (OMCL) PT Raised to $155 at Cantor Fitzgerald

November 2, 2021 11:38 AM EDT

Cantor Fitzgerald analyst Steven Halper raised the price target on Omnicell (NASDAQ: OMCL) to $155.00 (from $135.00) while maintaining a Neutral rating.

The analyst commented, "We reiterate our Neutral rating on OMCL shares but increase our 12-month, DCF-based price target to $155 (compared to $135 previously). This morning, November 2, the company reported 3Q21 results that were ahead of our estimates and FactSet consensus. Revenue was $296 million compared to our estimate of $284 million. Revenue... More

Omnicell's (OMCL) Central Pharmacy Dispensing Service Selected by Tucson VA Medical Center

November 2, 2021 7:36 AM EDT

Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Tucson VA Medical Center has chosen the Companys... More